Most Read Articles
Elvira Manzano, 10 Jun 2020
Intranasal esketamine reduces depression symptoms in severely ill patients with major depressive disorder (MDD) and active suicidal ideation with intent, the double-blind randomized ASPIRE 1 study has shown.
Pearl Toh, 16 Jun 2020
Adding belimumab to standard maintenance therapy significantly improves renal response in patients with active lupus nephritis compared with standard therapy alone, according to the BLISS-LN study presented at the ERA-EDTA 2020 Meeting.
Audrey Abella, 15 Jul 2020
The type I interferon receptor antibody anifrolumab reduced disease activity and flares in patients with moderate-to-severe active systemic lupus erythematosus (SLE), results of the TULIP-1 and TULIP-2 trials have shown.
Pearl Toh, 10 Jul 2019
Esketamine nasal spray effectively and rapidly improves depressive symptoms in patients with treatment-resistant depression, making it the first antidepressant to be approved by the US FDA in a new drug class.

Product Highlight - RENVELA

24 Jul 2020

Product Characteristics:

  •  For phosphorus control in patients with Chronic Kidney Disease on dialysis.1
  •  The first non-calcium based phosphate binder the lowers progression of vascular calcification vs calcium based phosphate binder.2
  •  Renvela Powder indicated for the control of serum phosphorus in pediatric patients more than 6 years of age.3
  •  Sevelamer carbonate (Renvela) - SRP Php 56.4

References:
(1) Renvela Tablet Product Insert CCDS Version 4 Date of leaflet revision: September 2015
(2) Block GA, Raggi P, Bellasi A, Koolenga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kindey Int. 2007;71:438-441.
(3) St. Peter WL, Liu J Weinhandi E, Fan Q. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomize trial using claims data. Am J, Kidney Dus. 2008-51;445-454.
(4) Mercury Drugstore Price, updated June 2020.


Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Philippines digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 10 Jun 2020
Intranasal esketamine reduces depression symptoms in severely ill patients with major depressive disorder (MDD) and active suicidal ideation with intent, the double-blind randomized ASPIRE 1 study has shown.
Pearl Toh, 16 Jun 2020
Adding belimumab to standard maintenance therapy significantly improves renal response in patients with active lupus nephritis compared with standard therapy alone, according to the BLISS-LN study presented at the ERA-EDTA 2020 Meeting.
Audrey Abella, 15 Jul 2020
The type I interferon receptor antibody anifrolumab reduced disease activity and flares in patients with moderate-to-severe active systemic lupus erythematosus (SLE), results of the TULIP-1 and TULIP-2 trials have shown.
Pearl Toh, 10 Jul 2019
Esketamine nasal spray effectively and rapidly improves depressive symptoms in patients with treatment-resistant depression, making it the first antidepressant to be approved by the US FDA in a new drug class.